Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

New radio-theranostics approach shows promise in the fight against pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. Many PDAC tumors in early stage go undetected because they are not found using conventional imaging methods, including fluorodeoxyglucose positron emission tomography (PET) scans.

15 Oct 2023

UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.

13 Oct 2023

Study suggests a potential strategy to combat aggressive brain tumors

A new study has unraveled a crucial link between how cancer cells cope with replication stress and the role of Taurine Upregulated Gene 1 (TUG1). By targeting TUG1 with a drug, the researchers were able to control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors such as glioblastomas.

12 Oct 2023

Protein antigen from a childhood vaccine can help refocus the body's immune system against cancer

A University of Massachusetts Amherst team has demonstrated in theory that a protein antigen from a childhood vaccine can be delivered into the cells of a malignant tumor to refocus the body's immune system against the cancer, effectively halting it and preventing its recurrence.

10 Oct 2023

Discovery of a novel therapeutic target for pancreatic cancer

A novel amino acid transporter-based therapeutic target for pancreatic ductal adenocarcinoma (PDAC).

10 Oct 2023

Drug combo safely decreases pancreatic cancer growth in mice

A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

9 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

New method can help researchers map pancreatic cancer development

Pancreatic cancer is one of the deadliest forms of cancer. This is largely due to the cancer being detected at a late stage. In addition, treatment options for pancreatic cancer are limited.

5 Oct 2023

Real-time live tissue sensitivity assay could be used as a personalized strategy for pancreatic cancer

A new research paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, "Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma."

19 Sep 2023

AACR Cancer Progress Report provides latest statistics on cancer research and treatment

Today, the American Association for Cancer Research (AACR) released the 13th edition of its annual Cancer Progress Report, which chronicles how basic, translational, and clinical cancer research and cancer-related population sciences-;primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)-;remain vitally important to improving health and saving lives.

13 Sep 2023

Unlocking the secret drivers of deadly pancreatic cancer: New target offers hope for treatment

Researchers identify a super-enhancer-regulated RNA-binding protein cascade that drives the growth of pancreatic ductal adenocarcinoma, a deadly form of pancreatic cancer. The discovery offers a promising new avenue for targeted therapy, potentially sidestepping severe side effects associated with other treatments.

10 Sep 2023

NCCN publishes new guideline focused on preventing and treating cancer-associated blood clots

The National Comprehensive Cancer Network today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE).

8 Sep 2023

Enhanced recovery program shows promise in reducing opioid reliance after pancreatic cancer surgery

By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero.

6 Sep 2023

New liquid biopsy technology uses RNA "dark matter" to detect cancer

Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease.

31 Aug 2023

New research sheds light on role of KRAS mutations in pancreatic cancer

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.

24 Aug 2023

Lorazepam linked to shorter progression-free survival in pancreatic cancer patients

Patients with pancreatic cancer who took the benzodiazepine lorazepam (Ativan), commonly prescribed to treat anxiety during cancer treatment, had a shorter progression-free survival than patients who did not, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

17 Aug 2023

Researchers receive DoD grant to target chemotherapy resistance in pancreatic cancer

Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have been awarded a grant from the U.S. Department of Defense (DoD)'s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer.